FDA OKs Xeomin in fourth in­di­ca­tion; Nextbi­otix rais­es $8M for mi­cro­bio­me tech

→ The FDA has green-light­ed Merz North Amer­i­ca’s sup­ple­men­tal Bi­o­log­ics Li­cense Ap­pli­ca­tion (sBLA) for Xeomin for the treat­ment of ex­ces­sive drool­ing (chron­ic sial­or­rhea) in adult …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER